The Overhead Lie: Why Your Practice's 60% Is Hiding a Valuation Problem

You look at your overhead and you see a number. You compare it to the benchmark. The benchmark says 60 to 65%. Your number is 62%. You are average. You are fine.

You are not fine.

The 62% overhead that feels reasonable by ADA benchmarks is the same number a PE-backed DSO’s underwriting team will deconstruct into four distinct categories of liability — then use to justify a purchase price that is nowhere near what your broker projected.

This is not because the benchmark is wrong. It is because the benchmark measures the wrong thing. The ADA benchmark measures what dental practices actually spend. The institutional buyer’s benchmark measures something entirely different: what a practice should spend after every non-defensible cost is removed, every personal expense is stripped, every related-party transaction is adjusted to fair market value, and a 5 to 18% corporate management fee is added back in to reflect what operating under institutional infrastructure actually costs.

Those are not the same number. And the gap between them is not cosmetic.

On a $2 million collections practice, every 1% reduction in overhead on the institutional calculation generates $160,000 in additional enterprise value at an 8x multiple. The 10% spread between the ADA’s 65% historical average and the institutional buyer’s 55% target represents $3.2 million in enterprise value on the same practice — not because the clinical operations changed, but because the overhead was looked at through a different lens.

This post explains what that lens sees — and how to build the overhead architecture that survives it. Understanding EBITDA normalization is the foundation.

---

Two Benchmarks. Two Completely Different Practices.

The first thing to understand about dental practice overhead in an institutional transaction is that there are two distinct benchmarks operating simultaneously, and most founders only know one of them.

The ADA benchmark — published annually by the Health Policy Institute, tracked by Dental Economics and the Levin Group — measures what the average dental practice actually spends as a percentage of collections. The 2024 DE/Levin Group Annual Practice Survey confirms the national median overhead sits at approximately 62% of collections, with a significant cohort of practices operating closer to 65%. This benchmark is descriptive. It tells you where most practices are.

The institutional buyer’s benchmark — the standard applied by PE-backed DSOs during Quality of Earnings analysis — measures where a practice needs to be for the acquisition to generate its targeted return. Elite high-performing independent practices and scaled DSO platforms actively manage overhead to the 50 to 55% range. This benchmark is prescriptive. It tells you where the money is.

The 10% gap between these two benchmarks is not incidental. It is the core foundational thesis of private equity value creation in dental. When a DSO acquires a practice running at 62% overhead and brings it to 52% through centralized administrative functions, negotiated supply chain pricing, and economies of scale — on $2 million in collections, that 10% improvement generates $200,000 in additional annual EBITDA. At 8x, that is $1.6 million in institutional value creation that did not exist in the seller’s hands.

The buyer is not overpaying for your practice. They are paying for what your practice will become after they do what you could not do as a solo operator. The question for the seller is not whether this arbitrage exists. It is whether your overhead architecture lets you capture your share of it — or hands it to the buyer through the diligence process.

---

The Benchmark Table: What Each Category Actually Means at Exit

The following table synthesizes the ADA historical benchmark against institutional buyer standards for each overhead category. The gap between columns one and two is where valuation is made and lost.

Overhead Category	ADA Benchmark	Institutional Buyer Standard	Red Flag Threshold	What Buyers Do With This
Staff costs	25–28%	20–25%	>30%	Targets <25% through RCM centralization and administrative consolidation
Dental supplies	6–8%	5–7%	>8%	Projects immediate savings through corporate procurement formularies
Lab fees	8–10%	6–8%	>10%	Models vendor consolidation post-close; CAD/CAM adoption expected
Occupancy/rent	5–8%	4–7%	>9%	Cannot be reduced without relocation; permanently suppresses multiple
Equipment/depreciation	4–6%	3–5%	>7%	Signals over-leveraged technology purchasing
Marketing	1–3%	2–4%	>5%	Validated only if CAC yields predictable high-margin production
Technology/software	0–1%	1–3%	N/A	Higher spend viewed favorably if it reduces staffing or drives case acceptance
Owner compensation	Variable	MGMA 30th percentile	N/A	Total historical draw is irrelevant — buyer models replacement cost
Total overhead	60–65%	50–55%	>70%	The 10% delta is the PE value creation thesis

The categories that generate the most forensic attention are not the ones most founders watch. Staff costs and supplies get managed carefully because they are visible in the monthly P&L. The categories that ambush sellers are the ones that sit below the operating line or exist in structures that feel permanent: occupancy above 9%, owner compensation that cannot be cleanly normalized, and lab fees that reflect a failure to invest in digital workflow. Each of these produces a specific, calculable enterprise value reduction. Our forensic services are designed to identify these exact vulnerabilities before a buyer does.

---

The Overhead Problem Your P&L Can’t See: The Normalization Ambush

Here is where the overhead lie begins.

Your P&L shows 62% overhead. It feels reasonable. What it does not show — and what a buyer’s QoE team will calculate in the first week of diligence — is the normalized overhead figure. The overhead after every add-back and add-in has been applied. And that number is almost never what the seller expects.

Add-Backs: Overhead That Goes Up

Owner compensation is the largest single normalization in any dental transaction. The institutional buyer does not care what you paid yourself. They care what it will cost to replace you clinically.

If you generated $1,000,000 in personal clinical collections and drew $500,000 in total compensation, the buyer models your replacement at the MGMA benchmark — typically 30% of collections for a general dentist associate, or approximately $300,000. That $200,000 difference between what you paid yourself and what your replacement costs is added back to EBITDA. At 7x, that single adjustment creates $1.4 million in enterprise value. It also means your overhead percentage changes — the $200,000 that was in your “compensation” category disappears from the overhead calculation, making the practice look more efficient than it was under your ownership.

Related-party rent is the second major add-back target. Many dental founders own their building through a separate LLC and charge the practice below-market rent. If your practice pays $3,000 per month while the third-party FMV for the same square footage is $6,000, the buyer normalizes the rent upward — a negative adjustment that reduces EBITDA by $36,000 annually and increases your apparent overhead by 1.8% on a $2 million collections practice. The tax-efficient structure that reduced your apparent overhead is the same structure that inflates it during institutional underwriting.

Personal expenses run through the P&L are a third category. Auto leases, family member compensation above market rate, country club dues, personal continuing education travel, whole life insurance premiums — all removed from overhead and added back to EBITDA. This works in the seller’s favor. But undocumented, aggressive, or speculative add-backs are rejected by the buyer’s financial advisors. Every add-back must survive the QoE audit or it does not exist.

Add-Ins: Overhead That Goes Down — And Then Back Up

This is the adjustment that shocks sellers most.

Many solo practitioners present a P&L with 60% overhead and pride themselves on running a lean operation. What they fail to account for is that their 60% does not include the infrastructure cost of being an institution.

The 60% overhead you are proud of is subsidized by your unpaid labor as an administrator. The buyer’s algorithm does not work for free. The 5 to 18% management fee models the true cost of the infrastructure you never built.

In the current dental M&A landscape, nearly all PE-backed acquisitions are structured through a Management Services Organization (MSO) or DSO under the Corporate Practice of Medicine (CPOM) doctrine — a legal framework in approximately 33 states that prohibits non-dentist entities from owning a dental practice. The PE firm creates the DSO. The clinical practice remains legally owned by a licensed dentist. The practice pays the DSO a management fee under a Management Services Agreement for providing all non-clinical administrative infrastructure: revenue cycle management, HR, legal compliance, procurement, IT, and executive oversight.

That management fee — typically 5 to 18% of net collections — is the pro-forma corporate overhead allocation that a buyer adds into your EBITDA calculation to model the practice’s true post-close cost structure.

A seller presenting $1,000,000 in EBITDA on $3,000,000 in revenue sees a 33% margin. The buyer applies an 8% management fee — $240,000 — and the adjusted EBITDA drops to $760,000. The institutional margin is 25.3%, not 33%.

Sellers do not pay a management fee as independent operators because they are the management. The fee models the cost of the infrastructure they never built. And it applies regardless of how clean the P&L looks before normalization. This is one of the core mechanisms explored in the EBITDA normalization framework.

---

The Overhead Number Your P&L Is Hiding: Phantom EBITDA and the Suppressed Percentage

There is a third overhead problem that neither add-backs nor add-ins address — and it is the most forensically dangerous of the three.

When revenue is artificially inflated by non-compliant clinical billing, overhead as a percentage of that revenue is mathematically suppressed. The practice looks more efficient than it actually is. The EBITDA margin looks stronger. The valuation looks more compelling.

Then the clinical audit runs.

The buyer’s forensic team removes the non-defensible revenue from the top line. The expenses that generated that revenue — staffing costs, clinical supplies, facility costs — do not come out with it. They remain in the overhead calculation. As top-line revenue drops while expenses stay static, the overhead percentage spikes. The practice’s true, defensible overhead is revealed to be higher than the P&L ever showed. And the EBITDA margin collapses with it.

This is the mechanism by which Phantom EBITDA and overhead analysis are inseparable in an institutional transaction.

The CDT codes most responsible for artificial overhead suppression are the same ones we’ve covered across this series:

D2950 — Core Buildup: Clinically indicated when more than 50% of tooth structure is missing. Cotiviti benchmarks a compliant core buildup-to-crown ratio at approximately 40%. Practices billing D2950 on 80 to 100% of crown procedures are generating revenue that does not survive a clinical audit. When that revenue is removed from the top line, every overhead category as a percentage of defensible revenue increases.

D4341/D4342 — Scaling and Root Planing: Strictly defined by the number of teeth exhibiting active, diagnosed periodontal disease per quadrant. Upcoding D4342 to D4341 to capture higher reimbursement without six-point probing depth documentation and diagnostic radiographic support creates retroactive clawback liability. When payers downgrade these claims retroactively, the revenue disappears but the clinical labor cost that produced it does not.

D1110/D4910 — The Alternating Prophy Trap: Alternating prophylaxis and periodontal maintenance codes to maximize insurance payouts on documented periodontal patients is the most widespread compliance violation in dental hygiene departments. Buyers model the financial impact of transitioning these patients to compliant D4910-only billing — and because many commercial plans deny D4910 after a certain period, the buyer projects a significant reduction in hygiene revenue. That revenue reduction hits the overhead percentage hard, because hygiene department expenses are largely fixed.

D4381 — Localized Antimicrobial Delivery: Clinically indicated exclusively as adjunctive therapy for refractory periodontal pockets greater than 5mm that have failed to respond to initial SRP. Practices that apply D4381 as a standard protocol on every SRP patient on the same day of treatment — regardless of pocket depth response — are generating revenue that institutional buyers discount entirely as unsustainable under compliance scrutiny.

The forensic consequence of identifying these patterns is not a line-item EBITDA adjustment. It is a fundamental reclassification of the practice’s true overhead percentage. A practice reporting 58% overhead on $2.5 million in gross collections may have a true defensible overhead of 68% once $375,000 in non-compliant revenue is removed from the denominator. The apparent efficiency was a mathematical artifact of inflated revenue, not operational discipline.

---

Overhead Variance by Practice Size: What Scale Actually Does

The overhead percentage does not exist in isolation from the size of the practice generating it. Institutional buyers evaluate overhead within the context of collections volume — because fixed costs behave differently at different scales, and the same overhead percentage means very different things on a $750,000 practice versus a $2.5 million one.

Sub-$750,000 collections: Overhead routinely 70 to 80%. Fixed costs — rent, base administrative payroll, equipment leases — consume a disproportionate percentage because they are spread across limited clinical days and patient volume. These practices are not inefficient in the sense of wasted spending. They are inefficient in the sense that their cost structure requires more revenue than they are generating to achieve viable margins. Institutional buyers view these as add-on or tuck-in acquisitions at 5 to 7x EBITDA — if they transact at all.

$750,000 to $1.5 million collections: Overhead normalizes to 60 to 70%. Patient volume reaches critical mass sufficient to justify full-time administrative staff. The facility is functionally utilized. This is the standard solo practitioner tier. Standard market multiples apply.

$1.5 million to $2.5 million+ collections: Overhead frequently drops below 60%, often to the 52 to 58% range. Fixed costs are distributed across multiple producers and a productive hygiene department. Economies of scale begin to appear. This is the tier where institutional buyer interest sharpens and premium multiple consideration begins.

DSO platform level: 50 to 55% through centralized RCM, bulk procurement, and enterprise-wide administrative infrastructure that individual practices cannot replicate.

The practical implication for exit planning: a practice that is approaching the $1.5 million threshold but running at 67% overhead due to underutilized capacity or inefficient fixed cost structure is not approaching a premium transaction. It is approaching a conversation about why the practice has not yet achieved the scale its fixed cost base was built for. Addressing that gap — through hygiene department optimization, associate productivity, and scheduling efficiency — before going to market is the overhead improvement that generates enterprise value.

---

The Overhead Architecture That Survives Institutional Scrutiny

A practice with 60% overhead backed by compliant clinical coding, market-rate real estate leases, documented add-backs, and streamlined operational technology will yield a superior transaction outcome to a practice with apparent 52% overhead riddled with forensic red flags.

This is the conclusion the research supports and the conclusion that inverts the conventional wisdom about overhead management. Lower overhead is not the goal. Defensible overhead is the goal.

The distinction matters because the two paths to lower apparent overhead produce entirely different institutional outcomes:

Path 1 — Operational efficiency: Overhead is reduced through hygiene department productivity, centralized billing, negotiated supply pricing, scheduling density optimization, and technology investment that reduces administrative headcount. This overhead reduction is real, sustainable, and survives the forensic audit because the revenue it is measured against is equally real and sustainable.

Path 2 — Revenue inflation: Overhead appears lower because the denominator — total collections — is inflated by non-compliant CDT coding. The overhead percentage looks better. The EBITDA margin looks stronger. The practice looks more efficient. Until the clinical audit removes the non-defensible revenue and the overhead percentage spikes to its true level.

Institutional buyers can distinguish between these two paths in the first week of PMS extraction. The practice whose low overhead reflects operational discipline presents a forensically clean picture. The practice whose low overhead reflects inflated revenue presents a target.

Building the overhead architecture that survives institutional scrutiny requires three years of compliant CDT utilization within Cotiviti benchmark ranges, documented add-backs supported by MGMA data and third-party FMV appraisals, realistic management fee modeling before engaging a broker, and overhead reduction through operational efficiency rather than revenue inflation. The EBITDA Leakage Calculator quantifies where the specific gaps are, and our forensic engagement builds the documentation that makes them defensible.

---

The $160,000-Per-Point Calculation — And Why It Changes Everything

Return to the calculation from the opening: on a $2 million collections practice, every 1% reduction in overhead at an 8x multiple generates $160,000 in additional enterprise value.

This calculation works in both directions.

A practice that reduces overhead from 65% to 60% through operational efficiency — real overhead improvement on real revenue — generates $800,000 in additional enterprise value at 8x. That $800,000 does not require revenue growth. It does not require a higher multiple. It requires operational discipline applied five years before the transaction, when there is time to demonstrate the improvement through a 36-month clean trending period that a buyer’s underwriting team will reward.

A practice that appears to have reduced overhead from 65% to 60% through revenue inflation generates the same apparent enterprise value improvement on paper — and then loses it, plus a holdback, when the clinical audit runs.

The overhead lie is not that your 62% is too high. The overhead lie is that 62% means the same thing in your P&L as it does in an institutional underwriting model. It does not. And the distance between those two meanings is where the valuation is made or lost.

If you want to know what your overhead actually looks like through the lens that matters — the conversation starts here.